Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): A phase 3b study in refractory multiple myeloma

Blood

Volumn 128, Issue 4, 2016, Pages 497-503

  Dimopoulos, Meletios A ^a   Palumbo, Antonio ^b   Corradini, Paolo ^c   Cavo, Michele ^d   Delforge, Michel ^e   Di Raimondo, Francesco ^f   Weisel, Katja C ^g   Oriol, Albert ^h   Hansson, Markus ⁱ   Vacca, Angelo ^j   Blanchard, María Jesús ^k   Goldschmidt, Hartmut ^l   Doyen, Chantal ^m   Kaiser, Martin ⁿ   Petrini, Mario ^o   Anttila, Pekka ^p   Cafro, Anna Maria ^q   Raymakers, Reinier ^r   San Miguel, Jesus ^s   De Arriba, Felipe ^t   Knop, Stefan ^u   Röllig, Christoph ^v   Ocio, Enrique M ^w   Morgan, Gareth ^x   Miller, Neil ^y   Simcock, Mathew ^y   Peluso, Teresa ^y   Herring, Jennifer ^z   Sternas, Lars ^z   Zaki, Mohamed H ^z   Moreau, Philippe ^aa   more..

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f UNIVERSITY OF CATANIA   (Italy)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ LUND UNIVERSITY HOSPITAL   (Sweden)

^j UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^k HOSPITAL RAMÓN Y CAJAL   (Spain)

^l UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^m UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

ⁿ ROYAL MARSDEN HOSPITAL   (United Kingdom)

^o UNIVERSITY OF PISA   (Italy)

^p HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^q OSPEDALE NIGUARDA CA GRANDA   (Italy)

^r UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^s UNIVERSITY CLINIC OF NAVARRA   (Spain)

^t HOSPITAL MORALES MESEGUER   (Spain)

^u UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^v UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^w Centro de Investigacion del Cancer   (Spain)

^x UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^y Celgene International   (Switzerland)

^z CELGENE CORPORATION   (United States)

^aa HÔTEL DIEU   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; POMALIDOMIDE; ANTINEOPLASTIC AGENT; THALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BACKACHE; BURNING SENSATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONSTIPATION; COUGHING; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSESTHESIA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GAIT DISORDER; HUMAN; HYPESTHESIA; INFECTION; INSOMNIA; LEUKOPENIA; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MOTOR DYSFUNCTION; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE ATROPHY; MUSCLE SPASM; NAUSEA; NEURALGIA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POLYNEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REFRACTORY MULTIPLE MYELOMA; SENSORIMOTOR NEUROPATHY; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; THROMBOCYTOPENIA; THROMBOEMBOLISM; TOXIC NEUROPATHY; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE;

EID: 84979912946     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-02-700872     Document Type: Article

References (17)

1. Kumar SK, Lee JH, Lahuerta JJ, et al; International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study [published correction appears in Leukemia. 2012;26(5):1153]. Leukemia. 2012;26(1):149-157.
2. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24(1):22-32.
3. Rychak E, Mendy D, Miller K, et al. Overcoming resistance: the use of pomalidomide (Pom) and dexamethasone (Dex) in re-sensitizing lenalidomide (Len)-resistant multiple myeloma (MM) cells [abstract]. Haematologica. 2011;96(s1):s126. Abstract P-328.
4. Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26(11):2326-2335.
5. Ocio EM, Fernández-Lázaro D, San-Segundo L, et al. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. Leukemia. 2015;29(3):705-714.
6. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96(9):2943-2950.
7. Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123(12):1826-1832.
8. San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055-1066.
9. Dimopoulos MA, Weisel KC, Song KW, et al. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica. 2015;100(10):1327-1333.
10. Pomalyst (pomalidomide) [package insert]. Summit, NJ. Celgene Corporation; 2015.
11. Imnovid (pomalidomide) [summary of product characteristics]. Uxbridge, UK: Celgene Europe; 2015.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
13. Durie BGM, Harousseau JL, Miguel JS, et al; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.
14. Leleu X, Attal M, Arnulf B, et al; Intergroupe Francophone du Myélome. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Blood. 2013;121(11):1968-1975.
15. Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551-1560.
16. Song KW, Dimopoulos MA, Weisel KC, et al. Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma. Haematologica. 2015;100(2):e63-e67.
17. Weisel K, Dimopoulos M, Song KW, et al. Pomalidomide and low-dose dexamethasone improves health-related quality of life and prolongs time to worsening in relapsed/refractory patients with multiple myeloma enrolled in the MM-003 randomized phase III trial. Clin Lymphoma Myeloma Leuk. 2015;15(9):519-530.